Vaxcyte, Inc. Financials

PCVX

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$562.5M

YoY-21.0%

Vaxcyte, Inc.'s EBITDA was -$562.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.0% from the prior year.

Free Cash Flow

-$475.1M

YoY-51.8%

Vaxcyte, Inc. generated -$475.1M in free cash flow in fiscal year 2024, representing cash available after capital expenditures. This represents a decrease of 51.8% from the prior year.

Net Income

-$463.9M

YoY-15.3%

Vaxcyte, Inc. reported -$463.9M in net income in fiscal year 2024. This represents a decrease of 15.3% from the prior year.

EPS (Diluted)

$-3.80

YoY+8.2%

Vaxcyte, Inc. earned $-3.80 per diluted share in fiscal year 2024. This represents an increase of 8.2% from the prior year.

Cash & Debt

$387.9M

YoY-2.4%

5Y CAGR+45.7%

Vaxcyte, Inc. held $387.9M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

$0.00

Vaxcyte, Inc. paid $0.00 per share in dividends in fiscal year 2024.

Shares Outstanding

125M

YoY+31.0%

5Y CAGR+98.4%

Vaxcyte, Inc. had 125M shares outstanding in fiscal year 2024. This represents an increase of 31.0% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$476.6M

YoY+43.4%

5Y CAGR+59.9%

Vaxcyte, Inc. invested $476.6M in research and development in fiscal year 2024. This represents an increase of 43.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$22.4M

YoY+39.6%

5Y CAGR+79.8%

Vaxcyte, Inc. invested $22.4M in capital expenditures in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 39.6% from the prior year.

PCVX Income Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$476.6M+43.4%	$332.3M+96.1%	$169.5M+116.1%	$78.4M+6.6%	$73.6M+61.3%	$45.6M
SG&A Expenses	$92.9M+53.1%	$60.7M+52.5%	$39.8M+57.6%	$25.3M+57.7%	$16.0M+87.4%	$8.5M
Operating Income	-$569.5M-21.7%	-$468.0M-101.5%	-$232.3M-124.0%	-$103.7M-15.7%	-$89.6M-65.4%	-$54.2M
Interest Expense	$0	$0-100.0%	$2K-71.4%	$7K0.0%	$7K-82.5%	$40K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$463.9M-15.3%	-$402.3M-80.0%	-$223.5M-123.3%	-$100.1M-12.2%	-$89.2M-77.5%	-$50.3M
EPS (Diluted)	$-3.80+8.2%	$-4.14-20.3%	$-3.44-78.2%	$-1.93+36.1%	$-3.02	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$209.9M+8.1%	$194.2M+31.1%	$148.1M	N/A	$116.9M-11.1%	$131.5M+39.0%	$94.6M	N/A
SG&A Expenses	$32.4M+1.3%	$32.0M-1.9%	$32.7M	N/A	$23.0M+7.1%	$21.5M+8.0%	$19.9M	N/A
Operating Income	-$242.4M-7.1%	-$226.2M-25.1%	-$180.8M	N/A	-$139.9M+8.5%	-$153.0M-33.6%	-$114.5M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	N/A	$0	$0	$0	N/A
Net Income	-$212.8M-27.8%	-$166.6M-18.4%	-$140.7M	N/A	-$103.1M+19.9%	-$128.7M-35.4%	-$95.0M	N/A
EPS (Diluted)	$-1.56-27.9%	$-1.22-17.3%	$-1.04	N/A	$-0.83+24.5%	$-1.10-29.4%	$-0.85	N/A

PCVX Balance Sheet

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Total Assets	$3.5B+149.4%	$1.4B+39.9%	$1.0B+210.2%	$324.3M-17.4%	$392.8M+497.9%	$65.7M
Current Assets	$1.8B+63.1%	$1.1B+16.3%	$942.6M+267.7%	$256.3M-34.1%	$389.0M+530.2%	$61.7M
Cash & Equivalents	$387.9M-2.4%	$397.5M-52.4%	$834.7M+1109.9%	$69.0M-82.1%	$386.2M+554.8%	$59.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$205.5M+22.7%	$167.4M+218.6%	$52.6M+30.4%	$40.3M-14.2%	$47.0M-72.7%	$172.1M
Current Liabilities	$140.2M-3.5%	$145.3M+258.6%	$40.5M+41.1%	$28.7M-38.7%	$46.9M+324.0%	$11.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.3B+166.5%	$1.2B+30.1%	$953.6M+235.8%	$284.0M-17.9%	$345.8M+425.1%	-$106.4M
Retained Earnings	-$1.4B-50.2%	-$924.4M-77.0%	-$522.1M-74.8%	-$298.6M-50.4%	-$198.6M-81.6%	-$109.3M

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Total Assets	$3.2B-4.0%	$3.3B-2.2%	$3.4B-3.8%	$3.5B-1.4%	$3.6B+70.5%	$2.1B-0.2%	$2.1B+48.5%	$1.4B
Current Assets	$1.8B+3.0%	$1.7B0.0%	$1.7B-4.0%	$1.8B-19.2%	$2.2B+49.4%	$1.5B-2.3%	$1.5B+38.4%	$1.1B
Cash & Equivalents	$281.1M-8.4%	$306.7M-11.6%	$346.9M-10.6%	$387.9M-63.1%	$1.1B+102.5%	$518.7M-15.2%	$611.5M+53.9%	$397.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$278.7M+19.1%	$234.0M+31.4%	$178.1M-13.3%	$205.5M+44.6%	$142.1M+40.5%	$101.1M-5.8%	$107.3M-35.9%	$167.4M
Current Liabilities	$200.0M+29.5%	$154.5M+59.3%	$97.0M-30.8%	$140.2M+13.2%	$123.8M+49.4%	$82.8M-4.9%	$87.1M-40.1%	$145.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.9B-5.8%	$3.1B-4.0%	$3.2B-3.2%	$3.3B-3.3%	$3.4B+72.1%	$2.0B+0.1%	$2.0B+59.9%	$1.2B
Retained Earnings	-$1.9B-12.6%	-$1.7B-10.9%	-$1.5B-10.1%	-$1.4B-11.0%	-$1.3B-9.0%	-$1.1B-12.6%	-$1.0B-10.3%	-$924.4M

PCVX Cash Flow Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Operating Cash Flow	-$452.6M-52.5%	-$296.8M-74.0%	-$170.6M-40.5%	-$121.4M-160.3%	-$46.6M+1.1%	-$47.1M
Capital Expenditures	$22.4M+39.6%	$16.1M+175.0%	$5.8M-10.9%	$6.6M+467.5%	$1.2M-3.3%	$1.2M
Free Cash Flow	-$475.1M-51.8%	-$312.9M-77.3%	-$176.4M-37.9%	-$127.9M-167.8%	-$47.8M+1.2%	-$48.3M
Investing Cash Flow	-$2.0B-159.4%	-$773.3M-1136.8%	$74.6M+135.1%	-$212.3M-19113.4%	-$1.1M+7.5%	-$1.2M
Financing Cash Flow	$2.4B+282.7%	$639.8M-25.7%	$861.5M+4741.2%	$17.8M-95.3%	$374.9M+801.8%	$41.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Operating Cash Flow	N/A	N/A	-$166.3M	N/A	N/A	N/A	-$159.1M	N/A
Capital Expenditures	N/A	N/A	$5.4M	N/A	N/A	N/A	$5.7M	N/A
Free Cash Flow	N/A	N/A	-$171.7M	N/A	N/A	N/A	-$164.8M	N/A
Investing Cash Flow	N/A	N/A	$123.3M	N/A	N/A	N/A	-$451.1M	N/A
Financing Cash Flow	N/A	N/A	$759K	N/A	N/A	N/A	$818.2M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PCVX Financial Ratios

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-13.2%+15.4pp	-28.6%-6.4pp	-22.2%+8.6pp	-30.9%-8.1pp	-22.7%+53.8pp	-76.5%
Current Ratio	12.75+5.2	7.54-15.7	23.26+14.3	8.93+0.6	8.30+2.7	5.58
Debt-to-Equity	0.06-0.1	0.14+0.1	0.06-0.1	0.140.0	0.14+1.8	-1.62
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-6.7%-1.7pp	-5.0%-0.9pp	-4.2%	N/A	-2.9%+3.3pp	-6.2%-1.6pp	-4.5%	N/A
Current Ratio	8.83-2.3	11.11-6.6	17.70+4.9	12.75-5.1	17.880.0	17.88+0.5	17.42+9.9	7.54
Debt-to-Equity	0.10+0.0	0.08+0.0	0.060.0	0.06+0.0	0.040.0	0.050.0	0.05-0.1	0.14
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is Vaxcyte, Inc. profitable?

No, Vaxcyte, Inc. (PCVX) reported a net income of -$463.9M in fiscal year 2024.

What is Vaxcyte, Inc.'s earnings per share (EPS)?

Vaxcyte, Inc. (PCVX) reported diluted earnings per share of $-3.80 for fiscal year 2024.

What is Vaxcyte, Inc.'s EBITDA?

Vaxcyte, Inc. (PCVX) had EBITDA of -$562.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Vaxcyte, Inc.'s free cash flow?

Vaxcyte, Inc. (PCVX) generated -$475.1M in free cash flow during fiscal year 2024, representing cash available after capital expenditures.

What is Vaxcyte, Inc.'s operating cash flow?

Vaxcyte, Inc. (PCVX) generated -$452.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Vaxcyte, Inc.'s total assets?

Vaxcyte, Inc. (PCVX) had $3.5B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Vaxcyte, Inc.'s capital expenditures?

Vaxcyte, Inc. (PCVX) invested $22.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Vaxcyte, Inc. spend on research and development?

Vaxcyte, Inc. (PCVX) invested $476.6M in research and development during fiscal year 2024.

How many shares does Vaxcyte, Inc. have outstanding?

Vaxcyte, Inc. (PCVX) had 125M shares outstanding as of fiscal year 2024.

What is Vaxcyte, Inc.'s current ratio?

Vaxcyte, Inc. (PCVX) had a current ratio of 12.75 as of fiscal year 2024, which is generally considered healthy.

What is Vaxcyte, Inc.'s debt-to-equity ratio?

Vaxcyte, Inc. (PCVX) had a debt-to-equity ratio of 0.06 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Vaxcyte, Inc.'s return on assets (ROA)?

Vaxcyte, Inc. (PCVX) had a return on assets of -13.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.